EXPORT CITATION

Chapter-112 Risk Evaluation and Mitigation Strategies for Opioids

BOOK TITLE: Ramamurthy's Decision Making in Pain Management: An Algorithmic Approach

Author
1. MV Rana
ISBN
9789386261458
DOI
10.5005/jp/books/14128_113
Edition
3/e
Publishing Year
2018
Pages
3
Author Affiliations
1. University of Chicago Medical Center, Chicago, IL, USA
Chapter keywords
Risk evaluation and mitigation strategy, REMS, extended-release, ER, morphine ER, hydromorphone ER, oxycodone, oxymorphone ER, tapentadol ER, morphine-naltrexone ER, methadone

Abstract

This chapter describes the risk evaluation and mitigation strategies for opioids. Extended-release/long-acting (ER/LA) opioids were prescribed to approximately 3.8 million patients annually between 2000 and 2009. The longer lasting agents provide steady-state analgesia to negotiate daily pain. Chronic pain promotes disability, lost productivity and diminished quality of life. Opioids have been a standard treatment for various types of chronic pain. In 2011, the Food and Drug Administration (FDA) announced the REMS requirement for ER/LA opioids. Patient education and addiction risk, overdose and misuse represent the highlights of this program. REMS agents include morphine ER, hydromorphone ER, oxycodone, oxymorphone ER, tapentadol ER, morphine-naltrexone ER, methadone, fentanyl formulations, buprenorphine systems and naloxone (Suboxone).

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved